DDIT3 and diffuse large B-cell lymphoma: Furthermore, the risk of reduced LVEF between patients treated with CHOP+/−R versus CEpOP+/−R was similar even after adjustments for age, sex, co-morbidities (hypertension, diabetes mellitus, and history of heart disease), smoking status, BMI, histology subtype, molecular subtype of DLBCL, and use of rituximab (Figure 4A).